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Background:  Neisseria  meningitidis  serogroup  B (MnB)  is  a major  cause of invasive  meningococcal  disease
in infants.  A conserved,  surface-exposed  lipoprotein,  LP2086  (a factor H-binding  protein  [fHBP]),  is  a
promising  MnB  vaccine  target.  A bivalent,  recombinant  vaccine  targeting  the fHBP (rLP2086)  of  MnB  was
developed.
Methods:  This  phase  1/2 clinical  study  was  designed  to  assess  the  immunogenicity,  safety,  and  tolerability
of  a 4-dose  series  of  the  rLP2086  vaccine  at 20-, 60-, 120-,  or 200-g  dose  levels  in  vaccine-naive  infants
when  given  with  routine  childhood  vaccines.  The  study  was  to consist  of  two  phases:  a  single-blind
sentinel  phase  and  an  open-label  full enrollment  phase.  During  the  sentinel  phase,  randomization  of
subjects  to the  next  higher  dose  was  delayed  pending  a 14-day  safety  review  of  dose 1  of the  preceding
dose  cohort.  The  full  enrollment  phase  was  to  occur  after completion  of  the sentinel  phase.
Results:  Local  reactions  were  generally  mild  and  adverse  events  infrequent;  however,  after  only  46 infants
were randomized  into  the  study,  fever  rates  were  64%  and  90%  in subjects  receiving  one  20-  or  60-g
rLP2086  dose,  respectively.  Most  fevers  were  <39.0 ◦C.  Only  2 subjects  in the 20-g  group  and  1  subject
◦ ◦in  the  60-g  group  experienced  fevers  >39.0 C; no  fevers  were  >40.0 C.  Due  to these  high  fever  rates,
the  study  was  terminated  early.  No  immunogenicity  data  were  collected.  This  report  discusses  the  safety
and acceptability  of  rLP2086  in  infants  after  one  20- or 60-g  dose.
Conclusion:  Due  to  the  high  fever  rate  experienced  in  the  20-  and  60-g groups,  rLP2086  in the  current
formulation  may  not  be  acceptable  for infants.. Introduction
Neisseria meningitidis is a major cause of bacterial sepsis and
eningitis, often associated with high mortality rates and per-
anent sequelae in survivors [1]. Rates of invasive disease are
ighest in infants and adolescents/young adults, with serogroups
, B, C, Y, and W being responsible for most cases [1]. Infection
ith A, C, Y, and W can be prevented with capsular polysaccharide
onjugate vaccines; however, polysaccharide conjugate vaccines
∗ Corresponding author at: Pﬁzer Vaccine Research, 500 Arcola Road, Collegeville,
A  18926, USA. Tel.: +1 484 865 5424; fax: +1 845 474 4243.
E-mail address: john.perez@pﬁzer.com (J.L. Perez).
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.049
264-410X/© 2014 Published by Elsevier Ltd.© 2014  Published  by Elsevier  Ltd.
are not effective against N. meningitidis serogroup B (MnB), which
accounts for 33% of meningococcal infections in the United States
and the majority in Europe [2–4].
Lipoprotein LP2086, a human factor H-binding protein (fHBP),
was identiﬁed as a vaccine candidate [5]. The LP2086 gene is highly
conserved, with >83% sequence identity within the 2 identiﬁed sub-
families, labeled A and B, and is present in all strains included in a
database of 1837 invasive MnB  isolates [6]. Few strains have been
identiﬁed to date that do not express fHBP [7,8]. Preclinical stud-
ies showed that a bivalent, recombinant LP2086 (rLP2086)-based
vaccine containing equal amounts of subfamily A and B proteins
could elicit serum bactericidal antibodies capable of killing diverse
MnB  strains [5,9]. Phase 1 and 2 studies in healthy toddlers, chil-
dren, adolescents, and adults showed the bivalent rLP2086 vaccine
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o be well tolerated and immunogenic in these patient populations
10–15].
The primary objectives of this study were to assess the immuno-
enicity, safety, and tolerability of a 4-dose series of bivalent
LP2086 vaccine at 1 of 4 dose levels given with routine child-
ood vaccines in vaccine-naive infants. The safety data are reported
erein.
. Materials and methods
.1. Study design
This phase 1/2, randomized, multicenter study conducted
rom January/February 2009 to January 2011 in healthy infants
onducted in Spain (ClinicalTrials.gov identiﬁer NCT00798304)
lanned to enroll 744 subjects. Assuming a 70% seroconversion rate,
60 subjects per group provided ≥95% power to demonstrate ≥50%
eroconversion rate for 1 subfamily A strain and 1 subfamily B strain
f both vaccine matched and heterologous antigens.
The study was to be conducted in 2 stages. Stage 1 was  designed
o assess the safety and immunogenicity of the MnB  rLP2086 vac-
ine. Stage 1 of this study was single-blind and the sponsor and
tudy staff dispensing and administering the study drug were
nblinded. All other personnel, including the principal investiga-
or and parent/legal guardian, were blinded. Stage 2 was  designed
o evaluate the duration of immunity against MnB  for up to 4 years
fter the end of stage 1. In stage 2, the study was to be open-label
nd the parent/legal guardian were to be informed of the test arti-
le and dose level that the child received. The study was terminated
efore stage 2.
Stage 1 included 2 phases, the sentinel and full enrollment
hases. During the sentinel phase, 198 subjects were to be ran-
omly assigned using a computer program to receive 1 of 4
scending doses (20 g, 60 g, 120 g, and 200 g) of bivalent
LP2086 with routine childhood vaccines or routine vaccines alone
t 2, 4, 6, and 12 months of age (Fig. 1). Enrollment of subjects was
taggered, starting with the lowest dose cohort (20 g of rLP2086),
nrolling 33 subjects in a 2:1 ratio. Randomization of subjects
o the 60-g dose cohort was delayed pending a 14-day safety
eview of dose 1. Speciﬁcally, the trial was to be stopped by a
roject-independent safety review committee composed of spon-
or employees not involved in this study if ≥4 subjects at each dose
evel in the sentinel phase had severe erythema or swelling that
equired medical attention; ≥4 subjects had fever >40 ◦C occurring
7 days after vaccination; or local reactions, systemic events, or
ther adverse events (AEs) that might jeopardize safety. An ad hoc
afety evaluation was to be performed if any of these criteria were
et. After review of the 14-day post-dose 1 safety data for the 20-
g dose, sentinel cohort 2 (60 g of rLP2086) opened enrollment for
5 subjects in a ratio of 4:1. The remaining subsequent higher dose
roups were to be enrolled similarly after the 14-day post-dose 1
afety data were reviewed.
The full enrollment phase was to occur after completion of the
entinel phase; subjects were to be randomized using a computer
rogram in a 2:2:2:1 ratio to receive 60, 120, or 200 g of the
LP2086 vaccine with routine childhood vaccines (up to 546 sub-
ects; 156 subjects per dose level) or routine childhood vaccines
nly (up to 78 subjects). This study was conducted in accordance
ith International Conference on Harmonisation Guideline for
ood Clinical Practice and the Declaration of Helsinki. The protocol
as approved by the institutional review board at each site..2. Study population
Infants aged 42–98 days were in good health as determined
y medical history and physical examination. Exclusion criteriane 32 (2014) 5206–5211 5207
included any previous vaccination, previous anaphylactic reaction
to any vaccine component, contraindication to vaccination, any
clinically signiﬁcant chronic disease, history of culture-conﬁrmed
N. meningitidis or N. gonorrhea infection, receipt of blood products,
or impaired immunity. Parents or legal guardians of participants
gave written informed consent.
2.3. Vaccination
Subjects were to be randomly assigned to receive 1 of 4
ascending doses of the bivalent rLP2086 vaccine with routine child-
hood vaccines or routine vaccines only. The recombinant bivalent
rLP2086 vaccine was supplied as a liquid suspension in a pre-
ﬁlled ready-to-use syringe. Each 0.5-mL dose contains 10 g, 30 g,
60 g, or 100 g of puriﬁed rLP2086 proteins from each rLP2086
MnB  subfamily: strain M98  250771 (variant A05; subfamily A)
and strain CDC1573 (variant B01; subfamily B). Inactive ingre-
dients include polysorbate 80 and 0.25 mg  of Al3+ as AlPO4 in
histidine buffer at pH 6.0 [10]. The DTaP-Hib-HBV + IPV vaccine and
Prevenar® (Pﬁzer Inc, New York, NY, USA) were given concomi-
tantly as routine childhood vaccinations in the contralateral thigh
with a 23-gauge, 1-inch needle. One of the several meningococ-
cal C (e.g., Meningitec®, Neis-Vac®, or Menjugate®) and rotavirus
(RotaTeq® or Rotarix®) vaccines were administered according to
the prescribing information at 2 and 4 months of age or 2, 4, and
6 months of age (RotaTeq® only). Subjects were also scheduled to
receive the varicella and the measles, mumps, and rubella vaccines;
however, no subjects received these vaccinations due to early trial
termination.
2.4. Safety and reactogenicity
Caregivers recorded solicited reactions 7 days postvaccination
in an electronic diary. For erythema and swelling, the largest
diameter was  measured with a caliper and categorized as absent,
mild (0.5–2.0 cm), moderate (2.5–7.0 cm), or severe (>7.0 cm).
Tenderness was  recorded as not discernible, present, or inter-
fering with limb movement. For subjects who received bivalent
rLP2086 vaccine, only reactions at the bivalent rLP2086 vaccine
injection site were reported; reactions at the Prevenar® injection
site were reported for control subjects. Solicited systemic events
included fever (absent [rectal temperature <38.0 ◦C], mild [38.0 ◦C
to 39.0 ◦C], moderate [>39.0 ◦C to 40.0 ◦C], or severe [>40.0 ◦C]), irri-
tability, increased/decreased sleep, decreased appetite, and use of
antipyretic medication. Other AEs were considered unsolicited and
collected throughout the study. AEs were assessed for seriousness
and relationship to rLP2086.
2.5. Immunogenicity
The study was  terminated before the necessary samples were
obtained.
2.6. Statistical analysis
The safety analysis population included all subjects who
received 1 dose of rLP2086. Safety data were summarized using
descriptive statistics.
3. Results
Tolerability of the rLP2086 vaccine was reasonable after 22 sub-
jects received the 20-g dose; however, after 10 subjects received
the 60-g dose, 1 subject developed aseptic meningitis, triggering
a protocol-deﬁned pause and cumulative safety evaluation. Specif-
ically, approximately 10 h after receipt of a 60-g dose of rLP2086
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Fig. 1. Patient ﬂow diagram. *1 subject withdrew owing to a urinary tract infection. †1 subject withdrew owing to aseptic meningitis. ‡Randomization of subjects to the next
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accine, Prevenar®, Infanrix hexa®, Meningitec®, and Rotarix®, the
ubject developed a fever (39.0 ◦C). A lumbar puncture was per-
ormed, and initial results showed 500 cells (95% PMNs), protein
.5 mg/dl (normal), glucose 60 mg/dl (normal), and red blood cell
ount of 10 mm3. The subject was treated with cefotaxime and van-
omycin after the lumbar puncture; the fever cleared by the next
vening and the child remained afebrile and well. The workup did
ot identify a causative organism; blood and cerebrospinal ﬂuid
CSF) bacterial and viral cultures were negative; polymerase chain
eaction tests of the CSF were also negative. Although the aseptic
eningitis was ultimately considered not vaccine related by the
reating physician, review of safety data by a project-independent
afety committee revealed 80% of vaccine recipients at the 60-g
ose experienced mild to moderate fever (90% including the case
f aseptic meningitis). The sponsor decided to terminate the trial
fter the vaccine was deemed not acceptable in this population.
.1. Subject demographics and disposition
Forty-six subjects were randomized: 22 received 20 g rLP2086,
0 received 60 g rLP2086, and 14 received routine childhood vac-
ines only. Mean age was 65.5 days; 48% were girls; all were white.
ll subjects received 1 vaccine dose; no postvaccination blood sam-
les were drawn.
.2. Safety
At least 1 local reaction was reported for 11 (50%) subjects in
he 20-g group, 7 (70%) subjects in the 60-g group, and 5 (36%)
ubjects in the control group. The rates of all reactions, except ery-
hema, were lowest in the control group and highest in the 60-g
roup (Table 1). The most common local reaction was  tenderness,
ith a mean duration of 1.3 days, 2.7 days, and 1.0 day in the 20-
g, 60-g, and control groups, respectively. Five subjects receiving
LP2086 experienced tenderness that interfered with limb move-
ent.
Most subjects experienced ≥1 systemic event. The most com-
on  event was irritability, reported for 17 (77%), 9 (90%), and 9
64%) subjects in the 20-g, 60-g, and control groups. Rates of
he other systemic reactions and anti-pyretic medication use wereety data were evaluated after completion of each subsequent cohort in the sentinel
e sentinel phase, which did not occur due to early trial termination in the sentinel
lowest in the control group and highest in the 60-g group, with
the exception of decreased sleep (Table 1). Duration of events was
1.0–3.3 days.
Fever ≥38 ◦C was reported in the majority of rLP2086 vaccine
recipients: 14 (64%) in the 20-g group and 8 (80%) in the 60-g
group compared with 4 (29%) in the control group (Fig. 2). In most
cases, the temperature was 38.0–39.0 ◦C; 2 subjects in the 20-g
group and 1 subject in the 60-g group had fever of >39.0–40.0 ◦C.
No fevers were >40.0 ◦C. The mean duration of fever was  1.0–2.1
days. The subject with aseptic meningitis also reported a fever
between >39.0 and 40.0 ◦C, increasing to 90% the proportion of
vaccine recipients reporting fever after a dose of 60 g. The onlyMild 
(38.0°C–39.0°C)
Moderate
(>39.0°C–40.0°C )
Severe
(>40. 0°C )
Any
Fig. 2. Fever severity in subjects in the safety population. *Not including the case of
aseptic meningitis.
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Table  1
Reactogenicity and adverse events of the safety analysis population.
Reaction/event, n (%) Control n = 14 20 g rLP2086 n = 22 60 g rLP2086 n = 10
Local reactionsa
Tenderness (severity)
Presentb 2 (14.3) 5 (22.7) 3 (30.0)
Interfered with limb movement 0 1 (4.5) 4 (40.0)
Indurationc
Mild 2 (14.3) 1 (4.5) 2 (20.0)
Moderate 0 3 (13.6) 1 (10.0)
Erythemac
Mild 4 (28.6) 5 (22.7) 3 (30.0)
Moderate 0 1 (4.5) 0
Systemic eventsa
Irritability 9 (64.3) 17 (77.3) 9 (90.0)
Decreased appetite 5 (35.7) 15 (68.2) 7 (70.0)
Decreased sleep 3 (21.4) 12 (54.5) 0
Increased sleep 4 (28.6) 13 (59.1) 7 (70.0)
Medication to prevent symptoms 3 (21.4) 9 (40.9) 6 (60.0)
Medication to treat symptoms 6 (42.9) 11 (50.0) 7 (70.0)
Any  systemic event 12 (85.7) 21 (95.5) 10 (100.0)
Fevera
Absent (<38.0 ◦C) 10 (71.4) 8 (36.4) 2 (20.0)
Mild  (38.0 ◦C–39.0 ◦C) 4 (28.6) 12 (54.5) 7 (70.0)
Moderate (>39.0 ◦C–40.0 ◦C) 0 2 (9.1) 1 (10.0)
Severe (>40.0 ◦C) 0 0 0
Any  fever 4 (28.6) 14 (63.6) 8d (80.0)
Adverse events in >5% of subject population
Any adverse event 3 (21.4) 7 (31.8) 2 (20.0)
Gastroesophageal reﬂux disease 0 1 (4.5) 1 (10.0)
Infections and infestations 2 (14.3) 6 (27.3) 1 (10.0)
Urinary tract infection 0 2 (9.1) 0
Viral  infection 0 2 (9.1) 0
Aseptic meningitis 0 0 1 (10.0)
Nasopharyngitis 0 0 1 (10.0)
Respiratory tract infection 1 (7.1) 1 (4.5) 0
Respiratory tract infection viral 1 (7.1) 0 0
Asthma 1 (7.1) 0 0
Dermatitis 1 (7.1) 0 0
Conjunctivitis 1 (7.1) 0 0
a Subjects reporting event from electronic diary within 1–7 d.
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c Mild, 0.5–2.0 cm;  moderate, 2.5–7.0 cm;  severe, >7.0 cm.
d Not including the case of aseptic meningitis.
Nineteen unsolicited AEs were reported among 12 subjects (7
n the 20-g group, 2 in the 60-g group, and 3 in the control
roup), most of which were related to infection. Seven serious AEs
ere reported by 5 subjects, none of which were vaccine related:
 subjects in the 20-g group had bronchitis (2 cases in same
ubject), urinary tract infection (2 cases), viral infection, and res-
iratory syncytial virus bronchiolitis; and 1 subject in the 60-g
roup had aseptic meningitis; 2 subjects were withdrawn from the
tudy owing to AEs, neither of which were study related (aseptic
eningitis and urinary tract infection; Table 1).
. Discussion and conclusions
Although local reactions were generally mild or moderate and
Es were infrequent, fever rates ranged from 63% to 90% in infants
eceiving one rLP2086 dose. Most fevers were ≤39.0 ◦C, with only 2
ubjects in the 20-g group and 1 subject in the 60-g group expe-
iencing fever >39.0 ◦C; no reported cases were >40.0 ◦C. Despite
he fact that almost 80% of fevers were mild and no cases of severe
ever occurred in the 43 trial participants, the high overall fever
ate experienced in the 60-g group suggests that rLP2086 in the
urrent formulation is not acceptable for infants.
Similar to the study presented herein, reactogenicity of the
CMenB vaccine, Novartis’s fHBP-based MnB  vaccine currently
icensed in European Union, Canada, and Australia, was also exam-
ned in infants. Interestingly, fever rates were similar to those
bserved in the present study [16,17]. For example, in the mostrecent phase 3 study of 4CMenB administered with routine vacci-
nation in infants, 65% (1612/2468) of subjects experienced fevers
≥38.5 ◦C; fevers ≥40 ◦C occurred in 1% (29/2468) of subjects [17]. It
is possible that the OMV  component of 4CMenB contributes at least
some of the reactogenicity of this vaccine, as an OMV  meningococ-
cal B vaccine (MenNZB) developed to target a speciﬁc epidemic
strain of MnB  in New Zealand also elicited fever rates in infants
up to 45% at any dose, 8% of which were ≥39 ◦C; analgesic use
was reported for up to 67% of subjects at any dose [18]; another
study of MenNZB in infants in New Zealand showed similar results
[19]. However, without a head-to-head trial, direct comparison of
the reactogenicity of 4CMenB and the bivalent rLP2086 vaccine in
infants is difﬁcult.
The question remains as to why bivalent rLP2086 vaccine is not
acceptable in infants but is acceptable in other ages, as fevers were
rare and generally mild in toddlers (≥18 months of age; 0–31.6%)
[15] and adolescents (0–12.5%) [10,11] when administering a 20-
or 60-g dose. Studies in mice suggested that the presence of the
lipid tail increases immunogenicity of the vaccine, and thus, the lip-
idated rLP2086 protein was  used in the vaccine [5]. It is plausible
that reactogenicity in infants is caused by increased innate immune
response to the lipidated protein; however, the same lipidated
vaccine is safe and acceptable in toddlers [15] and adolescents
[10,11], suggesting an age-related reactogenic effect. Differences
in reactogenicity in infants compared with older age groups may
be due to age-related differences in innate immune function.
Speciﬁcally, studies have shown differences in complement protein
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oncentrations [20,21] and the phagocytic activity of neutrophils
n infants compared with older children [21]. However, although
nlikely, the possibility also remains that differences in reacto-
enicity in infants may  be related to a socio-psychological event
hat resulted in an increased reporting of fevers in this patient
roup.
Overall, a strength of this study lies in the power of its design to
uickly identify safety signals while exposing few subjects to the
accine. Although the study design was sufﬁcient to quickly deter-
ine acceptability of rLP2086 in this patient population, important
imitations are that early study termination precluded collection of
ny immunogenicity data and limited safety analysis to only 46 sub-
ects, leaving the possibility that high fever rates were an artifact
f small study numbers.
Although the rLP2086 vaccine is reactogenic in infants, previous
hase 1 and 2 studies suggest that the rLP2086 vaccine is acceptable
n other at-risk age groups including toddlers, children, adolescents,
nd young adults [10,12–15]. Based on the immunogenicity and
olerability proﬁle observed in these studies, the 120-g dose was
elected for further clinical development. Future studies of biva-
ent rLP2086 vaccine will aim to ﬁnd the lower age limit where the
accine becomes not acceptable. Future studies may  also consider
lternative administration protocols.
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